AR071523A1 - Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento - Google Patents
Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamentoInfo
- Publication number
- AR071523A1 AR071523A1 ARP090101533A ARP090101533A AR071523A1 AR 071523 A1 AR071523 A1 AR 071523A1 AR P090101533 A ARP090101533 A AR P090101533A AR P090101533 A ARP090101533 A AR P090101533A AR 071523 A1 AR071523 A1 AR 071523A1
- Authority
- AR
- Argentina
- Prior art keywords
- denotes
- het
- alkyl
- atoms
- carbon atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Estos compuestos son utiles para el tratamiento de enfermedades neurodegenerativas, infecciones bacterianas, asma, insuficiencia de organos, cáncer, problemas de transplante de organos, e injertos. Reivindicacion 1: Un compuesto de acuerdo con la formula (1) donde :::: denota un enlace unico o un doble enlace U denota CRc, CH, o S; V denota C o N; W denota N o CR1; Ra denota perfluoralquilo, A, NH-A, -NH-(CH2)p-A, Het-alquilo, o si X denota un enlace, también CO-Het, CO-N(H)2-m(A)m, COOA, CO, CS, o si X denota CO, SO, CS, también H, o si V denota C o si U denota S, también Ar o Het. Rb denota Ar, Het2, Rc denota H, alquilo, Ar, Het; Ar denota un anillo monocíclico o bicíclico, aromático carbocíclico que posee 6 a 14 átomos de carbono, que se encuentra no sustituido o monosustituido, disustituido o trisustituido por, Hal, CF3, OCF3, NO2, CN, perfluoroalquil, A, OH, NH2, COH, CONH2, NHCOA, -NHSO2A, -NHSO2-N(H)2-m(A)m, N(H)1-qAqCOA, N(H)1-qASO2-N(H)2-m(A)m, N(H)1-qAqCON(H)2-m(A)m, COOA, -SO2A, -SO2N(H)2-m(A)m, -SO2Het, o SO2Het2 o Ar denota el grupo (2); X denota CO, SO, CS o un enlace, Het denota un anillo heterocíclico, monocíclico o bicíclico, saturado, insaturado o aromático que posee 1 a 4 átomos de N, O y/o S, que se encuentra no sustituido o monosustituido, disustituido o trisustituido por alquilo, que posee 1 a 8 átomos de carbono, alcoxi que posee 1 a 8 átomos de carbono, Hal, CF3, OCF3, NO2, CN, perfluoralquilo, A, OA, OH, amino, CONH2, -NHCOA, -NHSO2-N(H)2-m(A)m, COOA, -SO2A, -SO2N(H)2-m(A)m, -SO2Het, o SO2Het2. Het2 denota anillo monocíclico saturado, insaturado o aromático heterocíclico que posee 1 átomo de N, O o S, que se encuentra no sustituido, monosustituido, disustituido o trisustituido por alquilo, que posee 1 a 8 átomos de carbono, alcoxi que posee 1 a 8 átomos de carbono, Hal, CF3, OCFJ, NO2, CN, perfluoroalquil, OA, CH, CONH2, -NHCOA, -NHSO2-N(H)2-m(A)m, COOA, SO2N(H)2-m(A)m, -SO2Het, SO2J, en donde denota un grupo alquilo que posee 1 a 6 átomos de carbono, o Het2 denota uno de los siguientes grupos: (3), m denota 0, 1 o 2; p denota 0,1,2,3,4; q denota 0 o 1, A es un alquilo ramificado o lineal que posee 1 a 12 átomos de C, donde uno o más, preferentemente 1 a 7 átomos de H se pueden reemplazar con Hal, Ar, Het, OR6, CN, CONR'R'' COOR6 o NR'R'' y donde uno o más, con preferencia 1 a 7 grupos CH2 no adyacentes se pueden reemplazar por O, NR6 o S yo por grupos -CH=CH- o -C:::C-, o denota cicloalquilo o cicloalquilalquileno que posee 3-7 átomos de C de anillo; R1, R2, R3 son cada uno de manera independiente H, Hal, CF3, alquilo; o Ar, R', R'' denotan cada uno de manera independiente H, Ar, Het, o A. R6 es H, un alquilo o hidroxialquilo ramificado o lineal que posee 1 a 12 átomos de C y sus derivados, solvatos, tautomeros, sales y estereoisomeros farmacéuticamente aceptables, con inclusion de sus mezclas en todas las relaciones.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08155525 | 2008-04-30 | ||
| US12683508P | 2008-05-07 | 2008-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071523A1 true AR071523A1 (es) | 2010-06-23 |
Family
ID=39764733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101533A AR071523A1 (es) | 2008-04-30 | 2009-04-29 | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR071523A1 (es) |
| WO (1) | WO2009133127A1 (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200911798A (en) | 2007-08-02 | 2009-03-16 | Amgen Inc | PI3 kinase modulators and methods of use |
| EP2444403A1 (en) * | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
| JP2011525535A (ja) * | 2008-06-24 | 2011-09-22 | 武田薬品工業株式会社 | ＰＩ３Ｋ／ｍＴＯＲ阻害剤 |
| EP2401273A1 (en) | 2009-02-27 | 2012-01-04 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| CA2755285C (en) | 2009-03-20 | 2014-02-11 | Yunxin Y. Bo | Inhibitors of pi3 kinase |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| MX339243B (es) | 2011-02-03 | 2016-05-18 | Vtv Therapeutics Llc | Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos. |
| EA036592B1 (ru) | 2012-06-13 | 2020-11-26 | Инсайт Холдингс Корпорейшн | Замещенные трициклические соединения как ингибиторы fgfr |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| TWI574962B (zh) * | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as inhibitors of FGFR |
| MX2015017011A (es) * | 2013-06-10 | 2016-04-25 | Bayer Pharma AG | Compuestos nuevos para el tratamiento del cancer. |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
| CN104402875A (zh) * | 2014-12-25 | 2015-03-11 | 西安山川医药科技有限公司 | N-(2-氨基乙基)-n′-(6-取代-2-苯并噻唑基)脲及其盐类化合物的合成方法和用途 |
| US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
| KR102632018B1 (ko) | 2015-02-20 | 2024-02-02 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서의 이환식 복소환 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| MA54567A (fr) | 2016-01-05 | 2021-10-27 | Incyte Corp | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma |
| TW201803871A (zh) * | 2016-06-24 | 2018-02-01 | 英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| CN107641118B (zh) * | 2016-07-22 | 2020-11-06 | 爱科诺生物医药股份有限公司 | 具有细胞坏死抑制活性的化合物及其组合物和应用 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| ES2953025T3 (es) | 2017-10-02 | 2023-11-07 | 1St Biotherapeutics Inc | Compuestos de benzotiazol y métodos que usan los mismos para tratar trastornos neurodegenerativos |
| SI3697789T1 (sl) | 2017-10-18 | 2022-04-29 | Incyte Corporation | Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama |
| CA3099287A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| GB201811695D0 (en) * | 2018-07-17 | 2018-08-29 | Salvensis | Compounds for use in the treatment of fascioliasis |
| MX2021002551A (es) | 2018-09-05 | 2021-07-15 | Incyte Corp | Formas cristalinas de inhibidor de fosfoinositida 3-cinasa (pi3k). |
| KR20210122862A (ko) | 2019-02-22 | 2021-10-12 | 주식회사 퍼스트바이오테라퓨틱스 | 이미다조피리디닐 화합물 및 신경퇴행성 장애의 치료를 위한 그의 용도 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US10385046B1 (en) | 2019-03-19 | 2019-08-20 | 1ST Biotherapeutics, Inc. | Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders |
| CA3131337C (en) * | 2019-03-22 | 2023-10-17 | Genfleet Therapeutics (Shanghai) Inc. | Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof |
| CN113631554B (zh) * | 2019-03-28 | 2024-06-21 | 第一生物治疗股份有限公司 | 苯并噻唑化合物的药用盐、多晶型物及其制备方法 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091227B2 (en) * | 2000-02-07 | 2006-08-15 | Abbott Gmbh & Co. Kg | Benzothiazole derivatives |
| JP2003532728A (ja) * | 2000-05-05 | 2003-11-05 | コー セラピューティックス， インコーポレイテッド | ヘテロ二環式スルホンアミドおよび血小板ａｄｐレセプターインヒビターとしてのそれらの使用 |
| PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| WO2008016131A1 (fr) * | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique à cycles fusionnés |
| CA2662074A1 (en) * | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
| TW200911798A (en) * | 2007-08-02 | 2009-03-16 | Amgen Inc | PI3 kinase modulators and methods of use |
| CA2691448A1 (en) * | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
| PE20091268A1 (es) * | 2007-12-19 | 2009-09-19 | Amgen Inc | Derivados heterociclicos como inhibidores de pi3 quinasa |
-
2009
- 2009-04-29 AR ARP090101533A patent/AR071523A1/es unknown
- 2009-04-29 WO PCT/EP2009/055172 patent/WO2009133127A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009133127A1 (en) | 2009-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071523A1 (es) | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento | |
| CO6400220A2 (es) | Derivados de sulfonamida | |
| UY33779A (es) | ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas? | |
| CL2009001059A1 (es) | Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras. | |
| UY31063A1 (es) | Derivados de n-[6-amino-5-aril-piridin -2-il]-carboxamida, composiciones conteniéndolos, procedimientos de preparación, itermedios utilizados en la preparación y aplicaciones. | |
| ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
| CO6680683A2 (es) | Inhibiddores de la prostaglandina e2 sintasa-1 microsómica (mpges-1) y composiciones que los contienen, útiles en el tratamiento de enfermedades inflamatorias | |
| UY32793A (es) | Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos | |
| AR076076A1 (es) | Compuestos biciclicos y heterociclicos fusionados,composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
| ECSP12011857A (es) | Compuestos de dióxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| ECSP109906A (es) | Compuestos antivirales | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| UY32483A (es) | Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio | |
| DOP2011000279A (es) | Derivados de benzofuranilo usados como inhibidores de glucoquinasa | |
| CR11819A (es) | Compuestos de isoindolina 5-sustituidos | |
| UY31189A1 (es) | Compuestos heterocíclicos | |
| CL2012003211A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas | |
| ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| CO6361924A2 (es) | Nuevas lactamas como inhibidores de beta secretasa | |
| AR078613A1 (es) | Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores. | |
| DOP2009000177A (es) | Uso de derivados de acido de piranona sustituidos para el tratamiento del sindrome metabolico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |